GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+8.51%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$264M
AUM Growth
+$264M
(+13%)
Cap. Flow
+$16.9M
Cap. Flow
% of AUM
6.39%
Top 10 Holdings %
Top 10 Hldgs %
42.61%
Holding
61
New
24
Increased
14
Reduced
12
Closed
7
Top Buys
| 1 |
TG Therapeutics
TGTX
|
$16.5M |
| 2 |
Pfizer
PFE
|
$8.16M |
| 3 |
Johnson & Johnson
JNJ
|
$7.75M |
| 4 |
uniQure
QURE
|
$7.55M |
| 5 |
Akero Therapeutics
AKRO
|
$7.27M |
Top Sells
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$39.1M |
| 2 |
Invesco QQQ Trust
QQQ
|
$13.3M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$10.9M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$8.93M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$6.69M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
TG Therapeutics
TGTX
$4.65B
| $16.5M | 4.89% | +1,100,000 | New | +$16.5M |
|
2
Amylyx Pharmaceuticals
AMLX
$836M
| $13.9M | 4.12% | 475,000 +125,000 | +36% | +$3.67M |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $13.9M | 4.1% | 225,000 -10,000 | -4% | -$617K |
|
4
Ascendis Pharma
ASND
$11.8B
| $11.8M | 3.49% | 110,000 -20,000 | -15% | -$2.14M |
|
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $10.9M | 3.21% | 164,620 -135,380 | -45% | -$8.93M |
|
|
6
Akero Therapeutics
AKRO
$3.74B
| $10.5M | 3.11% | 275,000 +190,000 | +224% | +$7.27M |
|
7
Viking Therapeutics
VKTX
$3.04B
| $9.99M | 2.95% | 600,000 +300,000 | +100% | +$5M |
|
8
Vaxcyte
PCVX
$4B
| $8.43M | 2.49% | 225,000 +65,000 | +41% | +$2.44M |
|
|
CTIC
9
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $8.4M | 2.48% | 2,000,000 +150,000 | +8% | +$630K |
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $8.27M | 2.44% | 60,000 +5,000 | +9% | +$689K |
|
|
11
Pfizer
PFE
$141B
| $8.16M | 2.41% | +200,000 | New | +$8.16M |
|
|
RVNC
12
DELISTED
Revance Therapeutics, Inc.
RVNC
| $8.05M | 2.38% | 250,000 -50,000 | -17% | -$1.61M |
|
|
13
Johnson & Johnson
JNJ
$427B
| $7.75M | 2.29% | +50,000 | New | +$7.75M |
|
|
14
uniQure
QURE
$896M
| $7.55M | 2.23% | +375,000 | New | +$7.55M |
|
15
Madrigal Pharmaceuticals
MDGL
$9.76B
| $7.27M | 2.15% | 30,000 +10,000 | +50% | +$2.42M |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $7.16M | 2.12% | +200,000 | New | +$7.16M |
|
17
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.86M | 2.03% | 325,000 +175,000 | +117% | +$3.7M |
|
|
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.36M | 1.88% | 70,000 -430,000 | -86% | -$39.1M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $6.11M | 1.81% | 1,000,000 -300,000 | -23% | -$1.83M |
|
20
Astria Therapeutics
ATXS
$349M
| $5.99M | 1.77% | 450,000 | – | – |
|
21
Cogent Biosciences
COGT
$1.69B
| $5.94M | 1.75% | 550,000 -250,000 | -31% | -$2.7M |
|
22
Incyte
INCY
$16.5B
| $5.42M | 1.6% | +75,000 | New | +$5.42M |
|
23
Amicus Therapeutics
FOLD
$2.34B
| $5.27M | 1.56% | +475,000 | New | +$5.27M |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.21M | 1.54% | 140,000 -60,000 | -30% | -$2.23M |
|
25
Protagonist Therapeutics
PTGX
$3.67B
| $5.18M | 1.53% | +225,000 | New | +$5.18M |
|